Loading...
•
Sep 30, 2021
Corcept Therapeutics Q3 2021 Earnings Report
Reported an 11 percent revenue increase and GAAP diluted net income of $0.24 per share.
Key Takeaways
Corcept Therapeutics reported a strong third quarter with revenue of $96.1 million, an 11% increase from Q3 2020. GAAP diluted net income was $0.24 per share, and non-GAAP diluted net income was $0.30 per share. The company tightened its 2021 revenue guidance to $365 - $375 million.
Revenue of $96.1 million, an 11 percent increase from third quarter 2020
GAAP diluted net income of $0.24 per share, compared to $0.17 per share in third quarter 2020
Non-GAAP diluted net income of $0.30 per share, compared to $0.24 per share in third quarter 2020
Cash and investments of $495.2 million, compared to $471.6 million at June 30, 2021
Forward Guidance
Corcept narrowed its 2021 revenue guidance to $365 – $375 million. The company’s previous guidance was $355 – $385 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...